News

Panel backs approval of alirocumab, biologic injectable lipid-lowering drug

Publish date: June 9, 2015

 

AT AN FDA ADVISORY COMMITTEE MEETING

References

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

2015 class of ‘blockbuster’ drugs has plenty of heart
MDedge Cardiology
Testosterone therapy has neutral cardiovascular effects
MDedge Cardiology
TRACE-RA: Statin therapy may prevent CVD in RA
MDedge Cardiology
ILC: Statins linked to better outcomes in hepatitis C cirrhosis
MDedge Cardiology
Biologics cut cholesterol, may reduce mortality
MDedge Cardiology
Asymptomatic carotid stenosis and central sleep apnea linked
MDedge Cardiology
Chest pain: Risks of evaluation may outweigh benefits
MDedge Cardiology
AUA: Testosterone may not deserve its reputation as a cardiovascular culprit
MDedge Cardiology
Traditional diagnostic criteria miss OSA in coronary artery disease patients
MDedge Cardiology
FDA panel set to review two biologic lipid-lowering drugs for approval
MDedge Cardiology

Related Articles